About
Pharmaceuticals
Novo Nordisk A/S is a pharmaceutical company that specializes in diabetes care medications and devices. It produces insulin, GLP-1 analogs, obesity drugs, and biopharmaceuticals, as well as insulin pens, needles, and glucose monitoring devices.
Digital Innovation Hubs in major health-tech ecosystems worldwide to accelerate digital progress in defeating chronic diseases. The Hubs will connect with local start-ups and organizations, co-create solutions, and amplify Novo Nordisk's purpose. The network spans globally, with Hubs already launched in China, UK, Germany, Brazil, and Israel.
Identity
| Name | Novo Nordisk |
|---|---|
| Slug | novo-nordisk |
| Type / kind | multinational |
| Source _id | 2rsw586O2lD7oJovqvoYNcNeU26uA2H0PJgfrD1KnW9Fg9RoScMT2H |
Status
| Status | active |
|---|---|
| Status reason | Public on OMX on Oct, 1980;Public on NYSE on Sep, 1981; |
| Last update | 2026-05-17 |
Location
| HQ country | Denmark |
|---|---|
| HQ country code | DK |
| HQ city | Bagsværd |
| HQ address | Novo Alle 1, 2880 Bagsværd, Denmark |
Web & social
Classifications
Tags
pharmaceuticalsinnovation-centerdiabetes
Funding
| Total raised | — |
|---|---|
| Market cap | $147.4B |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}